Yatsen Holding Limited (YSG) Company Overview

Yatsen Holding Limited is a China-based beauty group listed on the New York Stock Exchange under ticker YSG. The Cayman Islands holding company sells color cosmetics and skincare across mass-market, premium and clinical price points. Its main brands are Perfect Diary, Little Ondine, Pink Bear, Galénic, DR.WU’s mainland China business and Eve Lom. The company’s ambition to become a world-class pioneer in beauty innovation reflects a shift from online makeup growth toward a multi-brand, research-led platform. The official company profile summarizes the portfolio.

How is the business organized?

Yatsen reports Color Cosmetics Brands, Skincare Brands and a small “Others” category. Operationally, it combines consumer research, product development, social commerce, marketplace distribution, stores and selected international channels. Most revenue and long-lived assets remain in China, while Eve Lom and Galénic add overseas heritage.

Why does Yatsen matter as a case study?

Yatsen is a useful case in whether a digitally native beauty operator can outgrow traffic-driven expansion. Its early model produced rapid online growth but also costly acquisition, discounting and weak operating profitability. The test is whether it can become a durable brand-and-science platform.

Yatsen earns revenue by selling beauty products directly through marketplaces, livestream platforms, Weixin channels and stores, and indirectly through e-commerce and offline distributors. Revenue is net of refunds and value-added tax. Product margins are high, but advertising, commissions, fulfillment and brand investment determine the real economics.

Which revenue stream drives the model?

Direct sales dominate. In FY2025, sales to end customers were RMB3.65 billion, or 84.9% of total revenue. Distributor sales were RMB641.3 million, or 14.9%, and other revenue was RMB10.5 million, or 0.2%. Direct selling gives Yatsen better access to consumer data and faster control of merchandising, but it also makes platform traffic costs and promotional intensity central to profitability.

Where does profit leak out?

The biggest pressure point is selling and marketing. In Q1 2026, gross margin reached 80.2%, yet selling and marketing consumed 72.2% of revenue. That gap explains why high product margins have not automatically produced operating profit. The model works only when brand investment creates repeat demand and pricing power faster than traffic acquisition costs rise.

The decisive change in Yatsen’s revenue mix is the rise of skincare. FY2025 Skincare Brands revenue increased 63.5% to RMB2.28 billion and represented 53.0% of group revenue. Color Cosmetics Brands revenue grew only 1.9% to RMB2.01 billion and fell to 46.7% of the mix. Other activities contributed RMB14.9 million, or 0.3%. The audited segment detail is available in Yatsen’s 2025 Form 20-F.

Why is skincare changing the economics?

Management says skincare products generally carry higher gross margins than color cosmetics. The shift therefore supports group margin expansion, while premium and clinical positioning can reduce reliance on pure trend cycles. The trade-off is that prestige skincare requires sustained scientific credibility, disciplined distribution and long-term brand investment rather than short-lived social-media campaigns.

What remains important about Perfect Diary?

Perfect Diary is still Yatsen’s first and largest brand, and it anchors the company’s awareness in Chinese color cosmetics. Its strategic role has changed from rapid assortment expansion toward “makeup skintification”: products such as Biolip Essence Lipstick and Bioface Essence Foundation use proprietary technologies to combine cosmetic effect with skincare claims. Success here would stabilize the color segment while reinforcing the group’s research narrative.

The quarter ended March 31, 2026 showed strong revenue growth but weaker near-term profitability. According to the Q1 2026 earnings release, revenue rose 22.5% year over year to RMB1.02 billion. Skincare revenue increased 58.5% to RMB574.2 million and reached 56.2% of the group total. Combined revenue from Galénic, DR.WU and Eve Lom grew 61.4%. Color cosmetics revenue declined 5.0%.

Why did faster sales not produce profit?

What is the immediate forward signal?

Management guided Q2 2026 revenue to RMB1.20–1.30 billion, implying roughly 10%–20% year-over-year growth. The useful research question is not simply whether Yatsen reaches the range. It is whether skincare growth remains strong while selling and marketing falls as a percentage of revenue, allowing operating leverage to reappear.

Yatsen’s history is best understood as a shift from digitally native makeup growth toward a diversified, research-led beauty group. The company began a comprehensive transformation in early 2022, emphasizing differentiated hero products, skincare expansion, disciplined promotion and sustained R&D. Its annual-report archive documents this progression.

1. 2016
   Foundation and Perfect Diary launch. The company entered beauty as a digitally native operator built around fast consumer feedback and e-commerce distribution.
2. 2019
   Little Ondine acquisition. Yatsen began expanding from a single flagship toward a brand portfolio.
3. 2020–2021
   Galénic, DR.WU mainland China and Eve Lom acquisitions. These transactions created premium and clinical skincare exposure and imported brand heritage.
4. 2022
   Strategic transformation begins. The focus moved toward sustainable growth, product efficacy, stronger brands and lower dependence on traffic-led expansion.
5. 2023
   Cosmax R&D and manufacturing hub opens. The joint-venture facility strengthened supply-chain coordination and product development.
6. 2024
   Global innovation R&D center opens in Shanghai. Yatsen added a central platform for formulation, testing and scientific collaboration.
7. 2025
   Skincare becomes the majority of revenue. The portfolio rebalancing became visible in reported financials, with skincare reaching 53.0% of sales.
8. 2026
   Convertible financing supports the next phase. New capital was designated for R&D, supply-chain integration, overseas expansion and possible M&A.

Yatsen has no single impregnable moat. Its advantage is a system of consumer feedback, fast product iteration, portfolio breadth, social commerce, scientific partnerships and flexible manufacturing. Defensibility depends on execution and cumulative learning.

How strong is the R&D platform?

At December 31, 2025, Yatsen reported 269 patent items: 10 utility-model, 158 design, 72 invention and 29 pending patents. FY2025 R&D expense was RMB137.3 million, or 3.2% of revenue, and 159 employees worked in R&D and product development. Facilities span Guangzhou, Shanghai, a Ruijin Hospital laboratory, a Cosmax-linked hub and Galénic’s French site. The test is whether ActiveAnchor, Biotec and Smartlock produce repeatable hero products.

Is the advantage durable?

The moat remains emerging. Higher skincare share and successful hero products support it; persistently high marketing intensity or new impairment would suggest that brand assets are not earning adequate returns.

Yatsen competes in one of the most crowded consumer categories in China. Its competitive set includes global beauty groups such as L’Oréal, Estée Lauder, Shiseido and Procter & Gamble; scaled domestic groups such as Proya; and specialist Chinese brands competing in makeup, clinical skincare and premium skincare. It also competes indirectly with new social-commerce brands that can emerge quickly on Douyin or RedNote. Yatsen’s filing emphasizes that rivals may have greater financial, technical and marketing resources, longer histories, larger customer bases and stronger distribution networks.

Where is Yatsen best positioned?

Yatsen is strongest where local digital agility and science-backed product storytelling overlap. Galénic and DR.WU can compete on efficacy and premiumization; Perfect Diary can compete on makeup innovation tailored to Chinese consumers. The weakest position is undifferentiated, promotion-heavy mass beauty, where switching costs are low and competitors can match price or content quickly.

FY2025 marked a substantial improvement from FY2024. Revenue increased 26.7% to RMB4.30 billion, gross profit rose 28.4% to RMB3.36 billion and gross margin improved to 78.2% from 77.1%. The operating loss narrowed to RMB185.8 million from RMB824.9 million, partly because FY2024 included RMB403.1 million of goodwill impairment. Net loss narrowed to RMB92.4 million from RMB710.2 million, while non-GAAP net income turned positive at RMB8.4 million. The full-year release provides the most accessible FY2025 financial summary.

What does the balance sheet say?

How should capital allocation be evaluated?

The first tranche of the 1.5% convertible notes closed on May 21, 2026, with Trustar Capital, Hillhouse affiliates and founder Jinfeng Huang participating. Proceeds target R&D, supply-chain integration, overseas expansion and M&A. The financing announcement adds flexibility but also dilution considerations.

Liquidity provides investment capacity, but FY2025 operating cash outflow of RMB94.7 million and Q1 2026 outflow of RMB90.0 million show that accounting improvement has not yet become consistent cash conversion.

Yatsen has a dual-class structure. Each Class A ordinary share carries one vote, while each Class B ordinary share carries 20 votes. As of February 28, 2026, founder, chairman and CEO Jinfeng Huang beneficially owned 34.3% of ordinary shares but controlled 90.7% of aggregate voting power. All directors and executive officers as a group owned 38.9% and controlled 91.3% of voting power. Hillhouse entities held 13.8% of ordinary shares but only 1.9% of voting power.

What does founder control change?

Founder control supports patient investment in premium brands and R&D, but it also concentrates decisions on capital allocation, financing and succession. Yatsen’s management page identifies Huang as founder, chairman and CEO, while the governance page sets out committee responsibilities.

The next phase will be judged by whether skincare growth becomes durable operating cash flow. Revenue alone is insufficient; brand momentum, marketing efficiency, inventory and governance must be assessed together.

Which risks could change the story?

What matters in a DCF or comparable-company analysis?

A DCF should separate high gross margin from sustainable free cash flow. Key variables are segment growth, marketing leverage, R&D, working capital and steady-state operating margin. Terminal assumptions require caution because beauty has low switching costs, rapid trend cycles and platform dependence. Comparables should reflect Yatsen’s faster skincare growth and lower profitability rather than rely on a simple revenue multiple.

Yatsen is becoming a skincare-led portfolio combining local digital execution, acquired premium brands and a growing research platform. FY2025—26.7% revenue growth, 78.2% gross margin and a narrower net loss—showed progress. Q1 2026 showed the constraint: skincare grew 58.5% and gross margin reached 80.2%, but marketing spending widened the operating loss and produced negative operating cash flow.

For students, Yatsen is a case in portfolio transformation and the difference between gross margin and economic profitability. The key question is whether repeat demand, product efficacy and channel diversification can reduce the cost of incremental sales. Until that conversion appears consistently in cash flow, the story remains execution-sensitive.